Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in South America has been experiencing steady growth in recent years.
Customer preferences: Customers in South America have been increasingly seeking out anti-hypertensive drugs due to the rising prevalence of hypertension in the region. This has been attributed to a number of factors, including an aging population, unhealthy diets, and sedentary lifestyles. Additionally, there is a growing awareness of the importance of managing hypertension to prevent serious health complications.
Trends in the market: Brazil has been the largest market for anti-hypertensive drugs in South America, accounting for the majority of sales in the region. However, other countries in the region, such as Colombia and Argentina, have been experiencing significant growth in their markets. This can be attributed to factors such as increasing healthcare access and government initiatives to improve healthcare outcomes.
Local special circumstances: In Brazil, the government has implemented a number of policies aimed at improving access to healthcare, including the provision of free medications for chronic diseases such as hypertension. This has helped to drive growth in the anti-hypertensive drug market in the country. In Colombia, the government has implemented a number of initiatives aimed at improving healthcare outcomes, including the expansion of health insurance coverage and the development of public-private partnerships to improve healthcare infrastructure.
Underlying macroeconomic factors: The South American economy has been experiencing steady growth in recent years, which has helped to drive demand for healthcare products, including anti-hypertensive drugs. Additionally, the region has a large and growing population, which provides a significant market for these products. However, there are also challenges facing the market, including regulatory hurdles and the high cost of drug development and manufacturing.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
